Shonali Midha

14PUBLICATIONS
105CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Regenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 23, 2026
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.

|Sep 12, 2026
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Mar 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga, Myra Robinson, James A Davis

|Oct 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Clifton C Mo, Yuxin Liu, Omar Nadeem

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

Pageof 3

Frequent Collaborators

7 joint publications

Aimaz Afrough

7 joint publications

Doris K Hansen

7 joint publications

Adam S Sperling

7 joint publications

Surbhi Sidana